Position in CDXS
as of Mar 31, 2026
· filed May 8, 2026
Position Value
$217,873
+$143,366 QoQ
Shares Held
133,665
+755.7% QoQ
Ownership
0.147%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2022
5 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in CDXS Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026LOS ANGELES CAPITAL MANAGEMENT LLC holds $681,191,908 across 153 Biotechnology names. CDXS ranks #67 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | INCY |
Incyte Corp
|
2,144,847 | $201,872,999 | |
| 2 | EXEL |
Exelixis, Inc.
|
3,102,634 | $133,071,972 | |
| 3 | REGN |
Regeneron Pharmaceuticals, Inc.
|
78,880 | $60,945,843 | |
| 4 | RPRX |
Royalty Pharma plc
|
971,927 | $46,623,338 | |
| 5 | HALO |
Halozyme Therapeutics, Inc.
|
689,915 | $44,589,206 | |
| 6 | CAI |
Caris Life Sciences, Inc.
|
2,289,602 | $40,938,083 | |
| 7 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
88,278 | $29,208,541 | |
| 8 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
64,937 | $28,996,967 |
All Filings in CDXS
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $217,873 | 133,665 | Shares | Sole | 2026-05-08 | |
| 2024-12-31 | $74,507 | 15,620 | Shares | Sole | 2025-02-04 | |
| 2024-09-30 | $53,838 | 17,480 | Shares | Sole | 2024-11-04 | |
| 2024-06-30 | $54,188 | 17,480 | Shares | Sole | 2024-08-05 | |
| 2022-06-30 | $792,606 | 75,775 | Shares | Sole | 2022-08-05 | |
| No filing history on record for this holder in this stock. | ||||||